Provided by Tiger Trade Technology Pte. Ltd.

Vaxcyte, Inc.

61.87
-0.7550-1.21%
Volume:170.82K
Turnover:10.57M
Market Cap:9.21B
PE:-8.09
High:63.05
Open:62.30
Low:61.23
Close:62.62
52wk High:65.00
52wk Low:29.87
Shares:148.81M
Float Shares:136.00M
Volume Ratio:0.49
T/O Rate:0.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-7.6496
EPS(LYR):-5.6333
ROE:-36.51%
ROA:-22.61%
PB:3.34
PE(LYR):-10.98

Loading ...

Vaxcyte Shareholders Reelect Directors, Approve Governance Measures

TIPRANKS
·
Jun 17

Vaxcyte shareholders re-elect three Class III directors at annual meeting

Reuters
·
Jun 17

Vaxcyte’s New VAX-A1 Trial: Early Move Into Group A Strep Vaccines

TIPRANKS
·
Jun 17

Vaxcyte (PCVX) Valuation Check As VAX A1 Begins Phase 1 Group A Strep Trial

Simply Wall St.
·
Jun 08

Vaxcyte COO Jim Wassil disposes of common shares worth $111,467.81

Reuters
·
Jun 04

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC)

TIPRANKS
·
Jun 04

Vaxcyte (PCVX) Has a New Rating from Mizuho Securities

TIPRANKS
·
Jun 03

Vaxcyte doses first participant in VAX-A1 study

TIPRANKS
·
Jun 03

Vaxcyte publishes investor presentation highlighting broad-spectrum pneumococcal vaccine pipeline lead VAX-31

Reuters
·
Jun 03

Vaxcyte - Expects Topline Data From Vax-a1 Phase 1 Study in H2 2027

THOMSON REUTERS
·
Jun 03

Vaxcyte Doses First Participant in Phase 1 Study Evaluating Vax-a1 for the Prevention of Disease Caused by Group a Streptococcus in Healthy Adults

THOMSON REUTERS
·
Jun 03

S&P 500 Futures Climb In Premarket Trading; MDA Space, ViaSat Lead

Dow Jones
·
May 26

Vaxcyte Down Over 10%, On Track for Largest Percent Decrease Since May 2025 -- Data Talk

Dow Jones
·
May 08

Analysts Have Conflicting Sentiments on These Healthcare Companies: Evotec AG (EVO), Vaxcyte (PCVX) and ACADIA Pharmaceuticals (ACAD)

TIPRANKS
·
May 08

Vaxcyte Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
May 07

Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate

Benzinga Earnings
·
May 07

Vaxcyte Q1 net loss widens to $320.6 million; R&D expenses jump to $312.8 million

Reuters
·
May 07

BRIEF-Vaxcyte Q1 Operating Expenses USD 345.85 Million

Reuters
·
May 07

Vaxcyte COO Jim Wassil disposes of USD 127,869 common shares

Reuters
·
May 02

Vaxcyte announces upcoming annual shareholder meeting

Reuters
·
Apr 24